Nandrolone decanoate
As of the edition of 20 October 2026, Nandrolone decanoate is a small molecule: marketed, first approved in 1986 (US); acts on AR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Deca-Durabolin
- First approved
- 12 June 1986 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Woodward Specialty
- Registered trials
- 10, 0 stopped early
- Disease areas
- Bones, joints and muscles; Hormones; Injuries; Nervous system; Urinary and reproductive; Blood and lymph
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Nandrolone decanoate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AR | Androgen receptor | P10275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 1 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 2 | 1 | 0 |
| Phase 4 | 2 | 0 | 2 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Woodward Specialty | Acquired holder | 2022 to now |
| Organon | Originator | 1986 to 2022 |